Oncology

Results from a study conducted by the Institute for Health Metrics and Evaluation show that new cases jumped 26.3% over the same period.

Small GISTs may cause no symptoms and may grow so slowly that they have no serious effects.

Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most often for patients.

The study authors sought to determine the proportion of states that elected to follow CDC recommendations by identifying each state’s COVID-19 vaccination webpage through keyword-based internet search and set out to identify information about vaccinations for patients with cancer.

Melanoma is responsible for 80% of skin cancer deaths.

The increasing economic burden of treatment may impact patient outcomes.

Burnout in pharmacy can be managed with the proper planning and the right techniques for your preference.

The goal of the financial counselor is to identify available funding for patient care in a timely manner, but the sheer number of resources and variables involved results in a long, tedious process.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the next steps for clinical research assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

More transparent drug pricing could improve patient care.

The FDA looks to address a lack of diversity in cancer drug trials.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Bladder cancer risk increases with age and is more common among men than women.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the results for all of the trial endpoints assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma.

The prescription-only crofelemer delayed-release tablets were developed using a sustainable, plant-based formula.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Holistic wellness and helping patients manage the toxins in their outside life are just a few of the focuses at Wobbly Arrow Wellness.

Modern technology is crucial to the provision of home infusions.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the primary endpoint in the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.

The cancer care system lags in comparison to other chronic health conditions in this key area.

Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on the safety and efficacy of Dara-KRd in the treatment of patients with newly diagnosed multiple myeloma.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Although marginal zone lymphoma is relatively rare, it contains a broad spectrum of conditions under it that require an individualized treatment selection process.

Multiple myeloma has remarkable genetic heterogeneity, which can make it challenging to identify proper prognostication and clinical management for patients.